Atezolizumab (Tecentriq) Approved for Some Patients with Triple-Negative Breast Cancer


Mar 28, 2019 - Accelerated approval for the use of Tecentriq, an immunotherapy drug, in combination with chemotherapy was granted for use in a specific subset of women with locally advanced or metastatic TNBC, whose tumor expressed the marker PD-L1, and who could not undergo surgery. However, there is a large population of women with TNBC tumors that do not express PD-L1, therefore we need to keep working on developing a targeted therapy that will be able help more women with TNBC.

Read the full article here